4-((1-((2,4-dichlorophenyl)sulfonyl)-3-hydroxyazetidin-3-yl)methoxy)-2-fluorobenzonitrile manufacturers
- PF-05214030
-
- $1520.00
-
2026-05-11
- CAS:1669444-50-1
- Purity:
- Supply Ability: 10g
|
| | 4-((1-((2,4-dichlorophenyl)sulfonyl)-3-hydroxyazetidin-3-yl)methoxy)-2-fluorobenzonitrile Basic information |
| | 4-((1-((2,4-dichlorophenyl)sulfonyl)-3-hydroxyazetidin-3-yl)methoxy)-2-fluorobenzonitrile Chemical Properties |
| Boiling point | 604.6±65.0 °C(Predicted) | | density | 1+-.0.1 g/cm3(Predicted) | | pka | 12.06±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | 4-((1-((2,4-dichlorophenyl)sulfonyl)-3-hydroxyazetidin-3-yl)methoxy)-2-fluorobenzonitrile Usage And Synthesis |
| Description | PF-05214030 is a novel potent TRPV4 antagonist (hTRPV4 IC50 4nM; rTRPV4 IC50 27nM). | | Uses | PF-05214030 is a TRPV4 antagonist (IC50: 4 and 27nM for hTRPV4 and rTRPV4 respectively). PF-05214030 reverses the reduction in bladder capacity caused by intravesical infusion of a TRPV4 agonist[1][2]. | | References | [1] Jiang Y, et al. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022 Mar 24;15(1):34. DOI:10.1186/s13045-022-01252-0
[2] Sarah Skerratt, et al. The Discovery and Optimisation of a Highly Selective Series of TRPV4 Antagonists. |
| | 4-((1-((2,4-dichlorophenyl)sulfonyl)-3-hydroxyazetidin-3-yl)methoxy)-2-fluorobenzonitrile Preparation Products And Raw materials |
|